Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IQVIA HOLDINGS INC.

(IQV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

IQVIA: Q3 Earnings Snapshot

10/21/2021 | 07:28am EST

DURHAM, N.C. (AP) _ IQVIA Holdings Inc. (IQV) on Thursday reported third-quarter profit of $261 million.

On a per-share basis, the Durham, North Carolina-based company said it had net income of $1.34. Earnings, adjusted for one-time gains and costs, were $2.17 per share.

The results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $2.13 per share.

The clinical testing company posted revenue of $3.39 billion in the period, which also beat Street forecasts. Seven analysts surveyed by Zacks expected $3.36 billion.

For the current quarter ending in December, IQVIA expects its per-share earnings to range from $2.37 to $2.47.

The company said it expects revenue in the range of $3.54 billion to $3.61 billion for the fiscal fourth quarter.

IQVIA expects full-year earnings in the range of $8.85 to $8.95 per share, with revenue ranging from $13.78 billion to $13.85 billion.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IQV at https://www.zacks.com/ap/IQV

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about IQVIA HOLDINGS INC.
12/06Aslan Pharmaceuticals Working With Iqvia Biotech on Clinical Trials
MT
12/06ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration
AQ
12/06ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration
CI
12/02IQVIA Decentralized Trial Suite Launches Mobile Research Nursing and Phlebotomy Service..
BU
12/02IQVIA Decentralized Trial Suite Launches Mobile Research Nursing and Phlebotomy Service..
CI
12/02INSIDER SELL : Iqvia Holdings
MT
12/01Teva Launches Epiduo Forte Gel's Generic Version in US
MT
12/01IQVIA Recognized as a Leader in BPO Solutions for Pharmaceutical Sales and Marketing
BU
11/19Amneal Pharmaceuticals Obtains FDA Approval for Difluprednate Ophthalmic Emulsion
MT
11/18IQVIA Launches New Grants/Funding Management Module for Its Orchestrated Customer Engag..
BU
More news
Analyst Recommendations on IQVIA HOLDINGS INC.
More recommendations
Financials (USD)
Sales 2021 13 830 M - -
Net income 2021 922 M - -
Net Debt 2021 10 634 M - -
P/E ratio 2021 57,2x
Yield 2021 -
Capitalization 51 638 M 51 638 M -
EV / Sales 2021 4,50x
EV / Sales 2022 4,11x
Nbr of Employees 77 000
Free-Float 74,2%
Chart IQVIA HOLDINGS INC.
Duration : Period :
IQVIA Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IQVIA HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Last Close Price 270,30 $
Average target price 300,29 $
Spread / Average Target 11,1%
EPS Revisions
Managers and Directors
Ari Bousbib Chairman, President & Chief Executive Officer
Ronald Earl Bruehlman Chief Financial Officer & Executive Vice President
Karl Guenault Chief Information Officer & Senior Vice President
W. Richard Staub President-Research & Development Solutions
Kevin C. Knightly President-Technology & Commercial Solutions
Sector and Competitors
1st jan.Capi. (M$)
IQVIA HOLDINGS INC.50.86%51 638
MODERNA, INC.170.27%114 479
LONZA GROUP AG24.16%58 572
SEAGEN INC.-16.39%26 777
CELLTRION, INC.-43.31%23 611
ICON PUBLIC LIMITED COMPANY42.88%22 677